Assessment of Substance Abuse Liability in Rodents: Self‐Administration, Drug Discrimination, and Locomotor Sensitization
互联网
- Abstract
- Table of Contents
- Materials
- Figures
- Literature Cited
Abstract
Assessing abuse liability is a crucial step in the development of a novel chemical entity (NCE) with central nervous system (CNS) activity or with chemical or pharmacological properties in common with known abused substances. Rodent assessment of abuse liability is highly attractive due to its relatively low cost and high predictive validity. Described in this unit are three rodent assays commonly used to provide data on the potential for abuse liability based on the acute effects of NCEs: specifically, self?administration, drug discrimination, and locomotor sensitization. As these assays provide insight into the potential abuse liability of NCEs as well as in vivo pharmacological mechanism(s) of action, they should form a key part of the development process for novel therapeutics aimed at treating CNS disorders. Curr. Protoc. Pharmacol. 58:5.62.1?5.62.22. © 2012 by John Wiley & Sons, Inc.
Keywords: abuse liability; self?administration; drug discrimination; locomotor sensitization; rat; mouse
Table of Contents
- Introduction
- Basic Protocol 1: Drug Self‐Administration in Rats
- Alternate Protocol 1: Self‐Administration in Drug‐Naïve Rats
- Basic Protocol 2: Drug Discrimination in Rats
- Basic Protocol 3: Locomotor Sensitization
- Reagents and Solutions
- Commentary
- Literature Cited
- Figures
Materials
Basic Protocol 1: Drug Self‐Administration in Rats
Materials
Alternate Protocol 1: Self‐Administration in Drug‐Naïve Rats
Materials
Basic Protocol 2: Drug Discrimination in Rats
Materials
|
Figures
-
Figure 5.62.1 Rat operant box. The photograph shows a rat operant box, as described in the text. It should be noted that the syringe pump is placed on top of the sound‐attenuating chamber during testing, but was placed on top of the operant box itself for the photograph. In the picture, the tubing and metal sheath are situated to the side of the operant box, leading from the swivel that can be seen at the very top of the inside of the sound‐attenuating chamber. The cue lights and the housing for the retractable levers can be seen situated on the exterior of the lower right wall of the operant box. The food hopper is clearly visible, connected to the magazine by a wide plastic tube, and with a manual over‐ride button to allow testing of pellet delivery. View Image -
Figure 5.62.2 Fluid swivel. The photograph shows a picture of an Instech fluid swivel (Model 375/22; Instech Laboratories, Inc.), used to allow delivery of the drug solution from the loaded syringe pump to the catheter port. View Image -
Figure 5.62.3 Intravenous catheterization of the external jugular vein in the rat. Panel (A ) shows the dorsum of the rat, shaved and prepared for surgery, with a black mark identifying the target for the catheter exit port. Panel (B ) shows an isolated external jugular vein, lying across the end of a Q‐tip, ready for placement of the suture threads and the insertion of the catheter. Panel (C ) shows the catheter located in the external jugular vein, fixed in place with sutures located above and below the silicon bead. Panel (D ) shows the end of the surgical procedure, with the catheter exit port connected to a syringe filled with heparinized saline. The wound has been closed with wound clips; Bacitracin will be applied before the syringe is disconnected, the catheter plug inserted, and the rat returned to a recovery cage. View Image -
Figure 5.62.4 Cocaine (A ) and morphine (B ) self‐administration in Sprague‐Dawley rats. Panel A illustrates how rats adjust their lever‐pressing behavior as the fixed‐ratio requirement is increased over days, in order to maintain stable levels of drug intake. The unit dose of cocaine was 0.3 mg/kg/infusion, and the time‐out was 20 sec. The rats were approximately 4 months old. Panel B illustrates how a variation in dose results in different levels of intake. Each dose was made available for five consecutive test sessions. Morphine was available on a fixed‐ratio 3 time‐out 20‐sec (FR3TO20s) schedule. In both studies, test sessions lasted 1 hr. Statistical method: Student Newman‐Keuls post‐hoc tests, following significant main effect of dose in a repeated‐measure ANOVA. Data are expressed as mean ± SEM. Asterisks ~undefined p < 0.05, ** p < 0.01) indicate significant differences compared to vehicle. View Image -
Figure 5.62.5 Nicotine discrimination in Sprague‐Dawley rats. Panels (A ) and (B ) depict the acquisition of the nicotine (0.4 mg/kg, i.p.) DS in 3‐ to 4‐month‐old Sprague‐Dawley rats ( n = 18). Open circles represent saline‐pretreatment sessions, and closed circles nicotine‐pretreatment sessions. Graphs (C ) and (D ) show the DS properties of nicotine and varenicline, respectively, in nicotine‐trained rats ( n = 9) at 18 months of age. The rats were previously exposed to a range of nicotinic agents. Data are expressed as mean ± SEM. Dotted lines indicate the thresholds for full (80%) versus absent (20%) generalization. View Image -
Figure 5.62.6 Locomotor sensitization induced by exposure to cocaine or D ‐amphetamine in C57Bl6/J mice. Panels (A ) and (C ) show total locomotor activity, measured daily during baseline (3 days of vehicle) or LS induction (5 days of vehicle, cocaine, or D ‐amphetamine) phases ( n = 10/group). Panels (B ) and (D ) show total locomotor activity measured after administration of a challenge dose of cocaine (10 mg/kg, i.p.) or D ‐amphetamine (1.5 mg/kg, i.p.) following the 10‐day wash‐out period. Statistical method: Student Newman‐Keuls post‐hoc tests, following significant interaction effects of Challenge X Exposure in a repeated‐measure ANOVA. Asterisks ~undefined p < 0.05) indicate a significant difference compared to either Day 1 of drug exposure (panels A and C) or the repeated vehicle‐acute challenge groups (panels B and D). View Image
Videos
Literature Cited
Literature Cited | |
Adriani, W., Macrí, S., Pacifici, R., and Laviola, G. 2002. Restricted daily access to water and voluntary nicotine oral consumption in mice: Methodological issues and individual differences. Behav. Brain Res. 134:21‐30. | |
Ator, N.A. and Griffiths, R.R. 2003. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 70:S55‐572. | |
Balster, R.L. and Bigelow, G.E. 2003. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70:S13‐S40. | |
Caggiula, A.R., Donny, E.C., Chaudhri, N., Perkins, K.A., Evans‐Martin, F.F., and Sved, A.F. 2002. Importance of nonpharmacological factors in nicotine self‐administration. Physiol. Behav. 77:683‐687. | |
Carr, K.D. 2002. Augmentation of drug reward by chronic food restriction: Behavioral evidence and underlying mechanisms. Physiol. Behav. 76:353‐364. | |
Colpaert, F.C. 1984. Cross generalization with LSD and yohimbine in the rat. Eur. J. Pharmacol. 102:541‐544. | |
Corrigall, W.A. and Coen, K.M. 1989. Nicotine maintains robust self‐administration in rats on a limited‐access schedule. Psychopharmacology 99:473‐478. | |
Donny, E.C., Chaudhri, N., Caggiula, A.R., Evans‐Martin, F.F., Booth, S., Gharib, M.A., Clements, L.A., and Sved, A.F. 2003. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: Implications for nicotine self‐administration and reinforcement. Psychopharmacology 169:68‐76. | |
Donovan, J. and Brown, P. 2006. Parenteral injections. Curr. Protoc. Immunol. 73:1.6.1‐1.6.10. | |
Fantegrossi, W.E., Murnane, K.S., and Reissig, C.J. 2008. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol. 75:17‐33. | |
Food and Drug Administration. 2010. Guidance for Industry. Assessment of Abuse Potential of Drugs. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. | |
LeSage, M.G., Shelley, D., Ross, J.T., Carroll, F.I., and Corrigall, W.A. 2009. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol. Biochem. Behav. 91:461‐467. | |
Licata, S.C. and Rowlett, J.K. 2008. Abuse and dependence liability of benzodiazepine‐type drugs: GABA(A) receptor modulation and beyond. Pharmacol. Biochem. Behav. 90:74‐89. | |
Malin, D.H. and Goyarzu, P. 2009. Rodent models of nicotine withdrawal syndrome. Handb. Exp. Pharmacol. 192:401‐434. | |
Paterson, N.E., Min, W., Hackett, A., Lowe, D., Hanania, T., Caldarone, B., and Ghavami, A. 2010a. The high‐affinity nAChR partial agonists varenicline and sazetidine‐A exhibit reinforcing properties in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 34:1455‐1464. | |
Paterson, N.E., Fedolak, A., Olivier, B., Hanania, T., Ghavami, A., and Caldarone, B. 2010b. Psychostimulant‐like discriminative stimulus and locomotor sensitization properties of the wake‐promoting agent modafinil in rodents. Pharmacol. Biochem. Behav. 95:449‐456. | |
Pickens, R. and Thompson, T. 1968. Cocaine‐reinforced behavior in rats: Effects of reinforcement magnitude and fixed‐ratio size. J. Pharmacol. Exp. Ther. 161:122‐129. | |
Smith, J.W., Mogg, A., Tafi, E., Peacey, E., Pullar, I.A., Szekeres, P., and Tricklebank, M. 2007. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157‐170. | |
Sorge, R.E. and Clarke, P.B. 2009. Rats self‐administer intravenous nicotine delivered in a novel smoking‐relevant procedure: Effects of dopamine antagonists. J. Pharmacol. Exp. Ther. 330:633‐640. | |
Tella, S.R., Ladenheim, B., and Cadet, J.L. 1997. Differential regulation of dopamine transporter after chronic self‐administration of bupropion and nomifensine. J. Pharmacol. Exp. Ther. 281:508‐513. | |
Vanderschuren, L.J. and Kalivas, P.W. 2000. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology 151:99‐120. | |
Vinkers, C.H., Olivier, B., Hanania, T., Min, W., Schreiber, R., Hopkins, S.C., Campbell, U., and Paterson, N. 2011. Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2‐73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur. J. Pharmacol. 668:190‐193. |